

Henry S H Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2469473/publications.pdf>

Version: 2024-02-01

24
papers

207
citations

1163117

8
h-index

1058476

14
g-index

24
all docs

24
docs citations

24
times ranked

253
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Retrospective Analysis of the Effectiveness of a Reduced Dose of Idarucizumab in Dabigatran Reversal. Thrombosis and Haemostasis, 2022, 122, 1096-1103. | 3.4 | 4 |
| 2 | Electronic FRail score as a predictor of treatment outcomes in older patients with diffuse large B-cell lymphoma. Journal of Geriatric Oncology, 2022, 13, 505-510. | 1.0 | 1 |
| 3 | Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Advances, 2022, 6, 3472-3479. | 5.2 | 12 |
| 4 | Māori and Pacific peoples with multiple myeloma in New Zealand are younger and have inferior survival compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). Clinical Lymphoma, Myeloma and Leukemia, 2022, , . | 0.4 | 0 |
| 5 | Fixed-dose three-factor prothrombin complex concentrates is safe and effective in warfarin reversal. Internal Medicine Journal, 2021, 51, 1884-1890. | 0.8 | 2 |
| 6 | Electronic FRail score may predict treatment outcomes in older adults with myeloma. Journal of Geriatric Oncology, 2021, 12, 515-520. | 1.0 | 2 |
| 7 | The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. Clinical Cancer Research, 2021, 27, 6323-6332. | 7.0 | 42 |
| 8 | Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. Internal Medicine Journal, 2021, 51, 1707-1712. | 0.8 | 1 |
| 9 | Efficacy and Tolerability of Gemcitabine-Based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell Transplant. Blood, 2021, 138, 4566-4566. | 1.4 | 0 |
| 10 | SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood, 2021, 138, 396-396. | 1.4 | 22 |
| 11 | Impact of age, sex, ethnicity, socioeconomic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand. British Journal of Haematology, 2020, 188, 692-700. | 2.5 | 13 |
| 12 | A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. Pathology, 2020, 52, 167-178. | 0.6 | 23 |
| 13 | Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial. Blood, 2020, 136, 11-12. | 1.4 | 19 |
| 14 | Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial. Blood, 2020, 136, 28-30. | 1.4 | 13 |
| 15 | Epidemiology of Acute Myeloid Leukaemia in New Zealand: A National Cancer Registry Analysis. Blood, 2020, 136, 36-37. | 1.4 | 0 |
| 16 | Conservative Management of Hemochromatosis without Long-Term Maintenance Venesections in Patients with Moderate Iron Burden. Blood, 2020, 136, 44-45. | 1.4 | 0 |
| 17 | Bortezomib Induction and Consolidation in Patients with Multiple Myeloma Who Received Frontline Autologous Stem Cell Transplant. Blood, 2020, 136, 33-33. | 1.4 | 0 |
| 18 | Significance of treatment response when managing patients with primary central nervous system lymphoma. Leukemia and Lymphoma, 2019, 60, 349-357. | 1.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBORd with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data. <i>British Journal of Haematology</i> , 2019, 187, 470-477. | 2.5 | 12 |
| 20 | ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma. <i>Blood</i> , 2019, 134, 5244-5244. | 1.4 | 4 |
| 21 | Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 225-234. | 0.4 | 7 |
| 22 | Single Centre Experience in Treating Elderly Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome with a Combination of Low Dose Cytarabine, Venetoclax and Fluconazole (VeLDAC-F). <i>Blood</i> , 2018, 132, 5220-5220. | 1.4 | 2 |
| 23 | Fixed Dose Carfilzomib Triplets in Lenalidomide Refractory Myeloma. <i>Blood</i> , 2018, 132, 3306-3306. | 1.4 | 1 |
| 24 | Current Review on High-Risk Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 96-108. | 2.3 | 24 |